JonesResearch initiated coverage of OnKure Therapeutics (OKUR) with a Buy rating and $32 price target. The clinical stage precision oncology ...

Eli Lilly agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash.

Jones Trading initiated coverage on OnKure Therapeutics Inc. (NASDAQ:OKUR) with a Buy rating and a price target of $32.00.

Eli Lilly’s chief scientific officer said the company purchased a cancer drug from the startup Scorpion Therapeutics because it "checked all the boxes." ...

Eli Lilly plans to acquire Scorpion's PI3Kα program for $2.5 billion, reinvesting Mounjaro and Zepbound profits to expand its ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Lilly will acquire Scorpion's experimental oral therapy, STX-478, which is currently being tested in early-stage trials for ...

JMP Securities analyst Silvan Tuerkcan maintained a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of ...

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

Eli Lilly has agreed to acquire Scorpion Therapeutics’ breast cancer treatment program for up to $2.5 billion in cash. The drugmaker said Monday it is acquiring Scorpion and its STX-478 program ...